New AI Test Could Detect Alzheimer's Early with Innovate UK Funding

Groundbreaking Study Receives Major Funding

Cumulus Neuroscience has received nearly £1.2M (~$1.5M USD) from Innovate UK to support a study that aims to validate AccelADx™, an innovative test for early detection of Alzheimer's dementia.

This support is part of Innovate UK's Small Business Research Initiative (SBRI), which helps businesses develop new ideas. The study, called Bio-Hermes 2, will involve 1,000 participants from the United States, Canada, and Europe.

Understanding AccelADx™ and Bio-Hermes 2

AccelADx™ is a new screening tool that uses artificial intelligence to detect subtle changes in brain activity related to memory recall, a key indicator of Alzheimer's disease.

The Bio-Hermes 2 study aims to compare these new biomarkers with current gold-standard diagnostic methods to see if they can be an effective, less invasive alternative.

Why Early Detection Matters

Accurate early diagnosis is crucial for managing Alzheimer's as it allows for timely intervention and better treatment options. Quicker, more precise methods like AccelADx™ can help patients take steps to slow disease progression.

This study will provide valuable data on how well digital biomarkers can replace more labor-intensive and costly techniques like PET scans.

Benefits for Diverse Populations

Bio-Hermes 2 will also study an ethnically diverse group of participants, ensuring that the findings are applicable to various demographics.

Having access to a broad dataset will enable Cumulus Neuroscience to fine-tune the AccelADx™ test for wide-scale use, potentially benefiting millions globally.

Enhanced Patient Care and Clinical Trials

Cumulus Neuroscience's NeuLogiq™ platform includes an FDA-cleared, UKCA-marked EEG headset that synchronizes with tablet-based assessments to simplify tracking brain function.

This technology allows for remote and in-clinic use, improving ease-of-use for patients, caregivers, and medical teams.

Improving Quality of Life

Early detection tools like AccelADx™ can significantly impact patients' quality of life by enabling earlier treatment plans and lifestyle adjustments. These measures can help slow the progression of Alzheimer's, providing more time for patients and their families to adapt.

Participants in this study will not only contribute to scientific breakthroughs but also pave the way for future Alzheimer's treatments and management strategies.

Conclusion

With the generous funding from Innovate UK, Cumulus Neuroscience is poised to make significant strides in Alzheimer's research. The Bio-Hermes 2 study and the innovation behind AccelADx™ mark a promising step forward in the fight against this devastating disease.

For more information on Cumulus Neuroscience and their pioneering work in neuroscience, visit www.cumulusneuro.com.